|
Name |
epicoccin G
|
| Molecular Formula | C20H26N2O6S2 | |
| IUPAC Name* |
(1R,4S,5S,9R,11R,14S,15S,19R)-5,15-dihydroxy-1,11-bis(methylsulfanyl)-3,13-diazapentacyclo[11.7.0.03,11.04,9.014,19]icosane-2,8,12,18-tetrone
|
|
| SMILES |
CS[C@@]12C[C@@H]3[C@H](N1C(=O)[C@@]4(C[C@@H]5[C@H](N4C2=O)[C@H](CCC5=O)O)SC)[C@H](CCC3=O)O
|
|
| InChI |
InChI=1S/C20H26N2O6S2/c1-29-19-7-9-11(23)3-5-13(25)15(9)21(19)18(28)20(30-2)8-10-12(24)4-6-14(26)16(10)22(20)17(19)27/h9-10,13-16,25-26H,3-8H2,1-2H3/t9-,10-,13-,14-,15-,16-,19+,20+/m0/s1
|
|
| InChIKey |
FZVZQZDYZWKKHU-RIJSRGPQSA-N
|
|
| Synonyms |
epicoccin G; Ent-Epicoccin G; CHEMBL1079829
|
|
| CAS | NA | |
| PubChem CID | 44614134 | |
| ChEMBL ID | CHEMBL1079829 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 454.6 | ALogp: | -0.9 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 166.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 30 | QED Weighted: | 0.616 |
| Caco-2 Permeability: | -5.016 | MDCK Permeability: | 0.00001840 |
| Pgp-inhibitor: | 0.372 | Pgp-substrate: | 0.579 |
| Human Intestinal Absorption (HIA): | 0.223 | 20% Bioavailability (F20%): | 0.006 |
| 30% Bioavailability (F30%): | 0.011 |
| Blood-Brain-Barrier Penetration (BBB): | 0.013 | Plasma Protein Binding (PPB): | 72.08% |
| Volume Distribution (VD): | 0.547 | Fu: | 38.26% |
| CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.135 |
| CYP2C19-inhibitor: | 0.029 | CYP2C19-substrate: | 0.903 |
| CYP2C9-inhibitor: | 0.249 | CYP2C9-substrate: | 0.119 |
| CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.052 |
| CYP3A4-inhibitor: | 0.074 | CYP3A4-substrate: | 0.977 |
| Clearance (CL): | 7.093 | Half-life (T1/2): | 0.908 |
| hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.245 |
| Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.872 | Maximum Recommended Daily Dose: | 0.866 |
| Skin Sensitization: | 0.402 | Carcinogencity: | 0.655 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
| Respiratory Toxicity: | 0.003 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003671 | ![]() |
1.000 | D0I1LH | ![]() |
0.232 | ||
| ENC003596 | ![]() |
0.745 | D04SFH | ![]() |
0.230 | ||
| ENC003673 | ![]() |
0.674 | D0IX6I | ![]() |
0.224 | ||
| ENC003573 | ![]() |
0.414 | D0KR5B | ![]() |
0.224 | ||
| ENC003617 | ![]() |
0.402 | D0X4RS | ![]() |
0.211 | ||
| ENC003809 | ![]() |
0.311 | D00YWP | ![]() |
0.209 | ||
| ENC000993 | ![]() |
0.263 | D0W3OS | ![]() |
0.207 | ||
| ENC004418 | ![]() |
0.254 | D0G8BV | ![]() |
0.207 | ||
| ENC003035 | ![]() |
0.248 | D06XMU | ![]() |
0.205 | ||
| ENC005140 | ![]() |
0.246 | D0Z1FX | ![]() |
0.205 | ||